Fulgent Genetics Inc reports results for the quarter ended June 30 - Earnings Summary

Fulgent Genetics

01/08/2025 14:32

Fulgent Genetics Inc FLGT.OQ reported quarterly adjusted earnings of 7 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 15 cents.  The mean expectation of three analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -23 cents to -10 cents per share.

Revenue rose 15.2% to $81.80 million from a year ago; analysts expected $76.21 million.

Fulgent Genetics Inc's reported EPS for the quarter was a loss of 62 cents​.

The company reported a quarterly loss of $18.96 million.

Fulgent Genetics Inc shares had fallen by 13.6% this quarter and lost 7.0% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 0.9% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is  "buy."

Wall Street's median 12-month price target for Fulgent Genetics Inc is $23.00, about 25.3% above its last closing price of $17.18

This summary was machine generated from LSEG data August 1 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.18
0.07
Beat
Mar. 31 2025
-0.18
0.04
Beat
Dec. 31 2024
-0.12
0.04
Beat
Sep. 30 2024
-0.15
0.31
Beat